If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

The deaths are also partly the result of medical successes: People are living longer, and more people are surviving heart ...

Preoperative use of SGLT2 inhibitors among patients with type 2 diabetes undergoing emergency surgery was not associated with ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

With studies showing potential for SGLT2 inhibitors in heart failure ... to consider its product’s role for heart failure patients who do not have diabetes. Heart failure is estimated to ...

A new study finds SGLT2 inhibitors like Jardiance and GLP-1 drugs like Ozempic provide different benefits depending on the ...

The effects of SGLT2 inhibitors on ... These work indirectly in the heart by improving cardiorenal hemodynamics and reducing fibrosis. These drugs do not address the underlying cause of metabolic ...

Opens in a new tab or window SGLT2 inhibitors were more cardioprotective ... Data on additional outcomes like end-stage kidney disease, heart failure, and medication-related harms weren't assessed.

In common with other complex diseases like heart failure ... an SGLT2 therapy. In it favour also is that it does not work as a diabetes medicine like the SGLT2s, so patiens on insulin do not ...

This drug is also used as a treatment option to prevent worsening chronic kidney disease (CKD) and is also used to reduce the risk of hospitalization in those with heart failure ... severe CKD do not ...